Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Nucana Plc ADR (NCNA)

Nucana Plc ADR (NCNA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,969
  • Shares Outstanding, K 2,092
  • Annual Sales, $ 0 K
  • Annual Income, $ -34,370 K
  • 60-Month Beta 0.92
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.45
Trade NCNA with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -3.31
  • Number of Estimates 4
  • High Estimate -2.50
  • Low Estimate -4.50
  • Prior Year -4.50
  • Growth Rate Est. (year over year) +26.44%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.40 +12.06%
on 04/19/24
7.85 -51.43%
on 03/26/24
-4.04 (-51.43%)
since 03/25/24
3-Month
3.40 +12.06%
on 04/19/24
19.41 -80.37%
on 03/13/24
-3.50 (-47.86%)
since 01/25/24
52-Week
3.40 +12.06%
on 04/19/24
23.75 -83.96%
on 06/26/23
-18.77 (-83.12%)
since 04/25/23

Most Recent Stories

More News
NuCana PLC Sponsored ADR (NCNA) Upgraded to Buy: What Does It Mean for the Stock?

NuCana PLC Sponsored ADR (NCNA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

NCNA : 3.81 (-0.78%)
Here's Why NuCana PLC Sponsored ADR (NCNA) is Poised for a Turnaround After Losing 26.5% in 4 Weeks

NuCana PLC Sponsored ADR (NCNA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts...

NCNA : 3.81 (-0.78%)
NuCana PLC Sponsored ADR (NCNA) Upgraded to Buy: What Does It Mean for the Stock?

NuCana PLC Sponsored ADR (NCNA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

NCNA : 3.81 (-0.78%)
Down 34.6% in 4 Weeks, Here's Why You Should You Buy the Dip in NuCana PLC Sponsored ADR (NCNA)

The heavy selling pressure might have exhausted for NuCana PLC Sponsored ADR (NCNA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street...

NCNA : 3.81 (-0.78%)
Nucana (NCNA) Receives a Buy from William Blair

E ratio of -1.26.

NCNA : 3.81 (-0.78%)
German Court Rules that Gilead’s Sofosbuvir Infringes NuCana’s ‘190 Patent

EDINBURGH, United Kingdom, July 11, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced that, following a comprehensive hearing on May 17, 2022,...

NCNA : 3.81 (-0.78%)
NuCana Announces Presentation on NUC-7738 at the European Hematology Association (EHA) 2022 Hybrid Congress

NUC-7738 Shows Promising Non-Clinical Activity in Acute Myeloid Leukemia NUC-7738 Kills AML Cells Resistant to Standard Chemotherapy Data Indicates...

NCNA : 3.81 (-0.78%)
NuCana Announces Receipt of NASDAQ Notice

EDINBURGH, United Kingdom, June 03, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced that it received written notification (the “Notification...

NCNA : 3.81 (-0.78%)
NuCana Reports First Quarter 2022 Financial Results and Provides Business Update

Initiated Randomized Phase 2 Study of NUC-3373 in Patients with Colorectal Cancer Initiated Phase 1b/2 Study of NUC-3373 in Combination with Other...

NCNA : 3.81 (-0.78%)
NuCana to Participate in the 2022 Jefferies Healthcare Conference

EDINBURGH, United Kingdom, June 01, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Don Munoz, Chief Financial Officer, will host...

NCNA : 3.81 (-0.78%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

NuCana PLC is a clinical-stage biopharmaceutical company. It focused on improving treatment outcomes for cancer patients by applying its phosphoramidate chemistry technology. The company's pipeline of products includes Acelarin, NUC-3373 and NUC-7738 which are in clinical stage. NuCana PLC is based in...

See More

Key Turning Points

3rd Resistance Point 4.49
2nd Resistance Point 4.24
1st Resistance Point 4.03
Last Price 3.81
1st Support Level 3.57
2nd Support Level 3.32
3rd Support Level 3.11

See More

52-Week High 23.75
Fibonacci 61.8% 15.98
Fibonacci 50% 13.57
Fibonacci 38.2% 11.17
Last Price 3.81
52-Week Low 3.40

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar